Rat Tetanus Toxoid IgM ELISA Kit

Name: Rat Tetanus Toxoid IgM ELISA Kit
SKU: DEIASL076
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum, plasma

Species Reactivity

Rat

Detection Method

Indirect-ELISA

Intended Use

This test kit allows rapid and quantitative measurement of rat anti-tetanus toxoid IgM levels in serum or plasma samples

Contents of Kit

No.	Components	Size	Storage Conditions
1	Tetanus Toxoid Coated 96-well Plate	12 strips of 8 wells	2-8°C
2	Enzyme Conjugate Reagent	11 mL	2-8°C
3	Standard Stock	lyophilized	Store < -20°C
4	20× Wash Solution	50 mL	2-8°C
5	Diluent	30 mL	2-8°C
6	TMB Reagent (One-Step)	11 mL	2-8°C
7	Stop Solution (1N HCl)	11 mL	2-8°C

Storage

1. The reference standard should be stored at -20°C for optimal stability.
2. All remaining kit components should be stored at 2-8°C.
3. The microtiter plate should be kept in a sealed bag with desiccant to minimize exposure to damp air. Test kit will remain stable for six months from the date of purchase provided that the components are stored as described above.

General Description

Evaluation of the levels of anti-tetanus toxoid IgM after immunization with tetanus toxoid provides a useful indicator of aspects of the immune response. The rat anti-tetanus toxoid IgM test kit developed by Creative Diagnostics, Inc. facilitates rapid and quantitative measurement of rat anti-tetanus toxoid IgM levels in serum or plasma samples.

Standard Curve

A typical standard curve with optical density readings at 450 nm on the Y-axis against anti-tetanus toxoid IgM concentrations on the X-axis is shown below. This curve is for the purpose of illustration only and should not be used to calculate unknowns.

Citations

Have you cited DEIASL076 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

Reagents for Diphtheria Vaccine Development

Reagents for Pertussis Vaccine Development

Reagents for Tetanus Vaccine Development

Immunoassays for Process-related Impurities

QA & Reviews

Customer Reviews

References

School-age children and adolescents suspected of having been to be infected with pertussis in Japan

VACCINE

Authors: Yasui, Yosuke; Mitsui, Toshikatsu; Nishimura, Tomoyasu; Uchida, Keiko; Inokuchi, Mikako; Mori, Masaaki; Tokumura, Mitsuaki; Nakayama, Tetsuo

Abstract

Many countries including Japan have adapted acellular pertussis vaccines combined with diphtheria and tetanus toxoids (DTaP). DTaP vaccine coverage is approximately >90%, but pertussis re-emergence has been observed since 2000 in Japan. In the present study, anti-pertussis antibodies were investigated among school-age children and adolescents from 2013 to 2015. The positive rate of anti-pertussis toxin (PT) antibodies was higher among children aged 12-13 years (60.0%. 95%Cl; 56.0-63.9%) in 2014 and 18-19 years (73.0%. 95%Cl; 61.4-82.6%) in 2013, compared with 6-7 years (47.1%. 95%CI; 40.7-53.6%). The mean PT antibody titer was higher among children aged 12-13 years (23.8 95%CI; 21.9-25.8) in 2014 and 18-19 years (29.3 EU/mI. 95%Cl; 23.0-35.6) in 2013, compared with 6-7 years (18.3 EU/mI. 95%Cl; 15.5-21.2). Distributions of pertussis antibodies and mean titers at their same grade of school-age were similar from 2013 to 2015. Although school-age children were immunized with 4 doses of DTaP, the data suggested the decay of vaccine-acquired immunity and possibility of asymptomatic infection in school age, indicating the additional DTaP vaccination before the entry of elementary school, preventing household contact. (C) 2018 Elsevier Ltd. All rights reserved.

Defective anti-polysaccharide IgG vaccine responses in IgA deficient mice

VACCINE

Authors: Furuya, Yoichi; Kirimanjeswara, Girish S.; Roberts, Sean; Racine, Rachael; Wilson-Welder, Jennifer; Sanfilippo, Alan M.; Salmon, Sharon L.; Metzger, Dennis W.

Abstract

We report that IgA(-/-) mice exhibit specific defects in IgG antibody responses to various polysaccharide vaccines (Francisella tularensis LPS and Pneumovax), but not protein vaccines such as Fluzone. This defect further included responses to polysaccharide-protein conjugate vaccines (Prevnar and Haemophilus influenzae type b-tetanus toxoid vaccine). In agreement with these findings, IgA(-/-) mice were protected from pathogen challenge with protein-but not polysaccharide-based vaccines. Interestingly, after immunization with live bacteria, IgA(+/+) and IgA(-/-) mice were both resistant to lethal challenge and their IgG anti-polysaccharide antibody responses were comparable. Immunization with live bacteria, but not purified polysaccharide, induced production of serum B cell-activating factor (BAFF), a cytokine important for IgG class switching; supplementing IgA(+/+) cell cultures with BAFF enhanced in vitro polyclonal IgG production. Taken together, these findings show that IgA deficiency impairs IgG class switching following vaccination with polysaccharide antigens and that live bacterial immunization can overcome this defect. Since IgA deficient patients also often show defects in antibody responses following immunization with polysaccharide vaccines, our findings could have relevance to the clinical management of this population. (C) 2017 Elsevier Ltd. All rights reserved.